Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
Globe Newswire•29/09/2026•07:00 ET
0
Key Highlights
- ➤NXC-201 (IMMX) delivers 89% CR rate, 40/45 patients, independently assessed
- ➤25 new patients: 21 CR and four MRD-negative
- ➤Four MRD-negative pending patients could lift CR rate to 98%, 44/45
- ➤No relapses, neurotoxicity, or enterocolitis observed to date
- ➤Final NEXICART-2 readout and BLA submission planned mid-2027
Expert Statements
Ilya Rachman, Chief Executive Officer of Immix Biopharma
“Today, patients with AL Amyloidosis face years of burdensome, continuous treatment. As a potential one-and-done treatment option, NXC-201 could liberate patients from that burden.”
Ilya Rachman, Chief Executive Officer of Immix Biopharma
“We are thrilled with NXC-201’s magnitude of effect across a broad range of relapsed/refractory AL Amyloidosis patients in NEXICART-2.”
Gabriel Morris, President of Immix Biopharma
“NXC-201’s complete response rate continues to increase over time, even as reported patient counts have now more than doubled.”
Gabriel Morris, President of Immix Biopharma
“We look forward to final readout, BLA submission and potentially making NXC-201 available to relapsed/refractory AL Amyloidosis patients at commercial launch.”
– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –
– To-date, all patients achieving MRD-negativity reached CR within one year of treatment –
Get started
Create a free account to read the full story.